Table 6.
Hazard ratios and 95% confidence intervals for COVID-19 death within 7 days of diagnosis in cancer patients.
| Variable | Number of deaths within 7 days of COVID-19 diagnosis | HRa | 95% CI |
|---|---|---|---|
| Sex | |||
| Female | 11 | 1.00 | Ref. |
| Male | 24 | 1.48 | (0.70–3.13) |
| Age | |||
| <60 | 6 | 1.00 | Ref. |
| >60 | 29 | 2.32 | (0.89–6.02) |
| SES | |||
| Low | 34 | 1.00 | Ref. |
| Middle | 0 | N/A | N/A |
| High | 0 | N/A | N/A |
| Ethnicity | |||
| White | 18 | 1.00 | Ref. |
| Black | 11 | 1.61 | (0.73–3.56) |
| Asian | 3 | 2.64 | (0.77–9.07) |
| Other | 2 | 3.20 | (0.74–13.94) |
| Number of comorbidities | |||
| 0 | 7 | 1.00 | Ref. |
| 1 | 10 | 1.20 | (0.40–3.61) |
| 2 | 10 | 1.53 | (0.51–4.60) |
| 3+ | 8 | 0.82 | (0.25–2.68) |
| Smoking history | |||
| Never | 14 | 1.00 | Ref. |
| Ever | 12 | 1.24 | (0.51–3.00) |
| Cancer type | |||
| Solid | 15 | 1.00 | Ref. |
| Haematological | 20 | 2.74 | (1.21–6.22) |
| Treatment Paradigm | |||
| No active treatment | 10 | 1.00 | Ref. |
| Radical/curative | 7 | 0.66 | (0.21–2.05) |
| Palliative | 14 | 1.29 | (0.49–3.38) |
| Time since cancer diagnosis | |||
| <1 year | 5 | 1.00 | Ref. |
| 1–2 years | 4 | 2.90 | (0.71–11.90) |
| 2–5 years | 12 | 4.81 | (1.47–15.69) |
| 5+ years | 12 | 4.41 | (1.38–14.06) |
| Performance status | |||
| 0–2 | 21 | 1.00 | Ref. |
| 3+ | 9 | 1.02 | (0.40–2.62) |
| Symptoms | |||
| Cough | 22 | 1.73 | (0.82–3.63) |
| Fever | 20 | 1.33 | (0.63–2.80) |
| Dyspnoea | 26 | 5.25 | (2.14–12.89) |
| GI symptoms | 6 | 1.04 | (0.39–2.71) |
| Time between first symptom and diagnosis | |||
| <7 days | 27 | 1.00 | Ref. |
| 7–14 days | 5 | 0.38 | (0.11–1.25) |
| >14 days | 1 | 0.22 | (0.03–1.63) |
| Abnormal Laboratory | |||
| Ferritin | |||
| T1 (14–704) | 1 | 1.00 | Ref. |
| T2 (771–1962) | 3 | N/A | N/A |
| T3 (1964–10,327) | 6 | N/A | N/A |
| CRP tertiles | |||
| T1 (1–50) | 2 | 1.00 | Ref. |
| T2 (51–145) | 10 | 0.62 | (0.73-53.57) |
| T3 (146–528) | 22 | 12.70 | (1.58–102.40) |
| Lymphocytes | |||
| ≤0.5 | 13 | 1.00 | Ref. |
| 0.6–0.8 | 5 | 0.67 | (0.21–2.15) |
| 0.9–1.2 | 6 | 1.33 | (0.41–4.29) |
| >1.2 | 10 | 1.20 | (0.36–3.98) |
| Albumin | |||
| T1 (15–29) | 16 | 1.00 | Ref. |
| T2 (30–37) | 13 | 1.10 | (0.47–2.58) |
| T3 (38–109) | 3 | 0.23 | (0.03–1.92) |
N/A refers to HRs with too few outcomes to be calculated.
aAdjustment as defined by the DAG (Supplementary Table 1 in Appendix).